DIVISLAB2021-01-012021-03-31in-bse-fin:OneOperatingExpenses01Member DIVISLAB2021-01-012021-03-31in-bse-fin:FourOperatingExpenses01Member DIVISLAB2021-01-012021-03-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member DIVISLAB2021-01-012021-03-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member DIVISLAB2021-01-012021-03-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member DIVISLAB2021-01-012021-03-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares DIVISLAB 2020-04-01 2021-03-31 2021-05-21 INR Lakhs Yearly true Cash Flow Indirect Single segment Pharmaceuticals 2021-01-01 2021-03-31 Audited Consolidated 17881900000.00 235200000.00 18117100000.00 7136100000.00 -3400000.00 -1319000000.00 2150800000.00 2100000.00 700800000.00 2754800000.00 11422200000.00 6694900000.00 0.00 6694900000.00 1370900000.00 303800000.00 1674700000.00 0.00 5020200000.00 0.00 0.00 0.00 0.00 5020200000.00 -14900000.00 5005300000.00 5020200000.00 0.00 -14900000.00 5005300000.00 530900000.00 2 18.91 18.91 0.00 0.00 18.91 18.91 1. The above Statement of consolidated audited financial results for the quarter and year ended 31st, March 2021, Statement of consolidated assets and liabilities and Statement of consolidated audited cash flows for the year and as at then ended March 31, 2021 ('Consolidated Statements') are prepared in accordance with Indian Accounting Standards ('lndAS') prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The same were, as reviewed by the Audit Committee, considered and approved by the Board of Directors at its meeting held on May 29, 2021. The same also were audited by the Auditors of the Company and their report contains no qualification. 2. The consolidated results include the audited financial results of the wholly owned subsidiaries Divis Laboratories (USA) Inc and Divi’s Laboratories Europe AG. 3. The Group is engaged in the manufacture of Active Pharmaceutical Ingredients, intermediates and nutraceutical ingredients; and the same constitutes a single reportable business segment as per Ind AS 108. 4. The Group does not have any discontinued operations and the Profit for the period / year represents the Profits from continuing operations only. 5. The Group considered the uncertainty relating to the COVID-19 pandemic in assessing the recoverability of its inventories, receivables and investments. As the Group is into essential manufacturing service, which is exempt from lockdown restrictions, the pandemic did not have any significant impact in its operations or its supply chain. In this regard, the Group has considered internal and external information while finalizing various estimates in relation to its financial statements upto the date of approval by the Board of Directors and has not identified any material impact on the carrying value of assets, liabilities or provisions. As the outbreak continues to evolve, the Group will continue to closely monitor any material changes to future economic conditions. 6. *Figures for the quarter ended 31.03.2021 and corresponding quarter ended 31.03.2020 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter of the respective financial years. 7. The Board of Directors of the company has recommended a dividend of Rs.20 per share of face value Rs.2 each i.e.,1000% for the financial year 2020-21, subject to approval of members at the ensuing annual general meeting. 8. Details of forex gain/(loss) are as given below: ( in lakhs) Quarter ended Year Ended 31.03.2021 31.12.2020 31.03.2020 31.03.2021 31.03.2020 (Audited)* (Unaudited) (Audited)* (Audited) (Audited) Forex gain/ (loss) 391 253 5710 (438) 8211 Forex gain has been included in Other Income and loss has been included in Other Expenses. Single segment 2020-04-01 2021-03-31 Audited Consolidated 69694000000.00 625600000.00 70319600000.00 23974400000.00 53100000.00 -786700000.00 8257600000.00 8700000.00 2555900000.00 9596200000.00 43659200000.00 26660400000.00 0.00 26660400000.00 6164600000.00 652900000.00 6817500000.00 0.00 19842900000.00 0.00 0.00 0.00 0.00 19842900000.00 4000000.00 19846900000.00 19842900000.00 0.00 4000000.00 19846900000.00 530900000.00 2 92415200000.00 74.75 74.75 0.00 0.00 74.75 74.75 Other Expenses 2754800000.00 Other Expenses 9596200000.00 8700000.00 -2813700000.00 -2654000000.00 0.00 724200000.00 -223300000.00 -14500000.00 -54900000.00 0.00 1748000000.00 0.00 597100000.00 0.00 2555900000.00 0.00 0.00 -1100000.00 50300000.00 0.00 -130600000.00 0.00 572400000.00 0.00 -26500000.00 0.00 0.00 0.00 58900000.00 0.00 -747900000.00 25912500000.00 0.00 0.00 0.00 6443200000.00 0.00 19469300000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1500000.00 9101900000.00 9740000000.00 458400000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 570100000.00 0.00 0.00 0.00 751300000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 332800000.00 7400000.00 0.00 0.00 8700000.00 0.00 0.00 -348900000.00 19871700000.00 0.00 19871700000.00 431500000.00 20303200000.00